Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 12/20 | 0.56 |
| ▸ | CDK8 | P49336 | 12/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578993 | 0.88 | CCNC (0.54) | CCNCCDK8CHEK2CYP2A6PRKCZ | |
| SCHEMBL4581027 | 0.82 | CCNC (0.44) | CCNCCDK8PIM1PRKCZ | |
| SCHEMBL5267766 | 0.82 | CCNC (0.61) | CCNCCDK8PIM1 | |
| SCHEMBL4580346 | 0.80 | CCNC (0.64) | CCNCCDK8CHEK2PIM1CHEK1 | |
| SCHEMBL5263350 | 0.80 | CCNC (0.64) | CCNCCDK8PIM1 | |
| SCHEMBL4580344 | 0.79 | CCNC (0.50) | CCNCCDK8SCN9APRKCZ | |
| SCHEMBL578403 | 0.79 | CCNC (0.67) | CCNCCDK8PIM1 | |
| SCHEMBL15741563 | 0.78 | CHEK2 (0.40) | CCNCCDK8CHEK2CHEK1 | |
| SCHEMBL15742747 | 0.78 | CCNC (0.69) | CCNCCDK8PIM1 | |
| SCHEMBL15742865 | 0.78 | CCNC (0.65) | CCNCCDK8CHEK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885CHEK2 2353/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885CHEK2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.